FutureTech II Acquisition Corp is a SPAC — a shell company with no operations. FutureTech II raised $115M in its February 2022 IPO, with proceeds held in trust, and is searching for a private company to acquire and take public. The SPAC's mandate focuses on U.S. technology companies, particularly in biomedical life sciences, AI, and robotics. FutureTech II has signed a merger agreement with Longevity Biomedical, a biopharmaceutical company targeting diseases associated with aging, and must complete the deal by August 18, 2025. If the merger closes, FutureTech II will rename itself Longevity Biomedical and list on Nasdaq under the ticker "LBIO." The SPAC is sponsored by FutureTech Partners II, which received founder shares — typically 20% of post-IPO shares — at a nominal cost, giving the sponsor significant upside if the deal closes and the combined company trades above $10. Public shareholders who don't want to participate in the deal can redeem their shares for their pro-rata share of the trust before the merger closes.